Table 1.
Comparison of baseline characteristics between the two groups
| Dapagliflozin (n = 497) | Comparators (n = 2973) | ||||
|---|---|---|---|---|---|
| % Available | Value | % Available | Value | P | |
| Age, y | 100.0 | 60.5 ± 9.3 | 100.0 | 67.3 ± 9.0 | <0.001a |
| Sex: Male, % | 100.0 | 61.0 | 100.0 | 59.8 | 0.625 |
| Current smoking, % | 22.3 | 23.4 | 22.3 | 20.1 | 0.426 |
| Diabetes duration, y | 100.0 | 12.5 ± 8.4 | 99.9 | 11.6 ± 7.8 | 0.012 |
| BMI, kg/m2 | 93.2 | 32.8 ± 5.8 | 91.3 | 29.9 ± 5.3 | <0.001a |
| SBP, mm Hg | 73.8 | 139.6 ± 18.3 | 78.3 | 137.8 ± 18.7 | 0.087 |
| DBP, mm Hg | 73.6 | 81.2 ± 10.3 | 78.2 | 78.7 ± 9.0 | <0.001a |
| FPG, mg/dL | 92.8 | 173.9 ± 52.3 | 91.2 | 157.1 ± 38.3 | <0.001a |
| HbA1c, % | 99.0 | 8.6 ± 1.3 | 98.8 | 7.9 ± 1.0 | <0.001a |
| Total cholesterol, mg/dL | 79.5 | 174.4 ± 40.6 | 79.3 | 170.1 ± 37.2 | 0.038 |
| HDL cholesterol, mg/dL | 77.9 | 46.5 ± 13.5 | 76.8 | 48.0 ± 13.5 | 0.035 |
| Triglycerides, mg/dL | 79.9 | 166.3 ± 133.3 | 78.1 | 147.0 ± 90.3 | <0.001a |
| LDL cholesterol, mg/dL | 73.4 | 95.8 ± 32.1 | 75.0 | 92.9 ± 31.3 | 0.104 |
| SGOT, U/L | 48.1 | 25.9 ± 20.1 | 48.6 | 23.0 ± 12.8 | 0.003 |
| SGPT, U/L | 53.1 | 33.0 ± 20.2 | 49.7 | 27.3 ± 17.6 | <0.001a |
| eGFR, ml/min/1.73 m2 | 83.1 | 87.8 ± 16.4 | 82.5 | 79.5 ± 18.7 | <0.001a |
| AER, mg/g | 63.2 | 104.9 ± 342.7 | 58.6 | 76.2 ± 261.3 | 0.089 |
| Associated GLM | |||||
| Insulin | 99.8 | 55.4 | 100.0 | 15.2 | <0.001a |
| Metformin | 99.8 | 99.2 | 100.0 | 79.7 | <0.001a |
| Other medications | |||||
| Antiplatelet | 87.3 | 48.6 | 86.7 | 54.6 | 0.022 |
| Statin | 87.3 | 65.0 | 98.4 | 59.2 | 0.023 |
| ACEi/ARBs | 87.3 | 72.6 | 86.7 | 71.3 | 0.577 |
| CCB | 87.3 | 25.1 | 98.4 | 20.1 | 0.016 |
| Betablockers | 87.3 | 31.6 | 98.4 | 26.7 | 0.032 |
| Diuretics | 87.3 | 9.7 | 86.7 | 23.2 | <0.001a |
| Complications | |||||
| Microangiopathy | 100.0 | 41.9 | 93.2 | 32.6 | <0.001a |
| Macroangiopathy | 86.5 | 32.8 | 83.3 | 36.8 | 0.115 |
Data are expressed as mean ± standard deviation, or as % where appropriate. Per cent of available data is reported for all variables.
Abbreviations: ACEi, angiotensin‐converting enzyme inhibitors; AER, albumin excretion rate; ARBs, angiotensin receptor blockers; BMI, body mass index; CCB, calcium channel blockers; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; GLM, glucose‐lowering medications; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; SBP, systolic blood pressure; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase.
a
Statistically significant after Bonferroni correction.